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Leishmania infantum is a protozoan parasite causing severe vector-borne visceral diseases both in humans and dogs. The latter are
the most important natural reservoir and therefore should be the main target of control measures. The real eﬃcacy of seropositive
dogs culling as a direct control method is still debated, and the new sensitivity of large part of population considers ethically
unacceptable thiskindofapproach. Treatmentofinfectious dogswithoneoftheavailable therapeuticprotocolsisrecommendable
as it allows to reduce parasite burdens and therefore the possibility of transmission of Leishmania infantum to vectors. Vaccination
hasbeenpr o v entobeav eryeﬀectivecontroltool,buttheabsenceofacommonlyrecognizeddiagnosticmethodabletodistinguish
vaccinate from seropositive individuals is still an important limit. Concerning indirect control methods, a number of studies have
demonstrated the eﬃcacy of topical insecticides treatment (collars, spot-on, and sprays) in reducing incidence and prevalence of
L. infantum. Also, the reduction of the odds of seroconversion in humans in endemic areas has been reported after the application
of indirect control measures on dogs. The contemporary use of direct and indirect methods is even more eﬀective in reducing
seroprevalence in dogs.
1.Introduction
Leishmania infantum is a protozoa, obligatory intracellular
parasite of mammalian macrophages. This parasite is trans-
mitted by phlebotomine sandﬂies causing severe vector-born
visceral infectious diseases: zoonotic visceral leishmaniosis
(ZVL) in human and canine leishmaniosis (CanL) in dogs.
Infected dogs, both owned and not, can be an important
threat to public health, because L. infantum has the domestic
dog as principal reservoir. To date, ZVL is endemic to large
areasofEurope,Asia,andAfrica,particularlyinthecountries
of the Mediterranean Basin [1, 2]. In Latin America ZVL is
linked to L. chagasi, now considered as a synonymous of L.
infantum and therefore included in the same species [3–5].
During the past years, the importance of ZVL public
health concerns has increased, considering the increase in
risk factors associated with environmental changes, human
migration, and, mostly, the presence of Leishmania infan-
tum- i n f e c t e dd o g si np r e v i o u sn o n e n d e m i ca r e a s .I nf a c t ,
the emergence of cases of ZVL in new territories is usually
preceded by an increase in the prevalence of CanL. An eﬀec-
tive control of CanL is therefore crucial for the prevention
of ZVL in humans: in particular, vector control through the
employment of repellent drugs seems to be an eﬃcient tool
for the reduction of seroprevalence [5–9]. Culling of infected
dogs is also used in some areas, but animal welfare concerns
could arise from this issue, and its real usefulness is debated:
epidemiological studies reported evidences of the ineﬃcacy
of ZVL control programs that provide for the elimination of
infected dogs [10–12]. Treatment of infected dogs reduces or
eliminates clinical signs, but it is not usually parasitological
curative [13] and treated dogs could still be capable of tran-
smittingtheparasite[14].Recently,acaninevaccinehasbeen
licensed in some countries and has been proved to be
an eﬃcient preventive tool in order to diminish both the
number of human and canine cases [1, 12]. However,
the use of this vaccine is still debated in many countries,
considering its possible eﬀect on the serological condition of
healthy vaccinated individuals and, therefore, on the eﬃcacy
of serological control campaigns [15, 16].2 Veterinary Medicine International
Here, after a wide description of ZVL and CanL clinical
and epidemiological aspects in humans and dogs, we con-
siderwhatis the state of the art aboutCanL controlmethods,
particularly regarding their eﬃcacy and feasibility for large
scale-control plans.
2.Leishmania infantum inHumans:
Zoonotic Visceral Leishmaniasis(ZVL)
Human leishmaniosis is a parasitic disease caused by intra-
cellular protozoan of the genus Leishmania. These parasites
infect many mammalian species, and the transmission from
one species to another happens through arthropods vectors,
mostly phlebotomine sandﬂies. Among 15 species of Leish-
mania, 13 have a zoonotic nature and cause severe diseases
transmitted from mammalian reservoirs to humans. There
are two main forms of zoonotic leishmaniosis: the zoonotic
visceral leishmaniosis (ZVL) and the zoonotic cutaneous
leishmaniosis (ZCL).
ZCL is less severe, usually not fatal and self-healing, but
responsible for a large number of cases, mostly in Latin
America and Middle East [17]. It is caused by many diﬀerent
species of the genus Leishmania, including dermotropic
L. infantum, but it is mostly due to L. major and other
species hosted by rodents and many tropical wild animals
(armadillos, sloths, and procavias). Clinical forms of ZCL
in humans usually consist of localized noduloulcerative
lesions; rarely these forms evolve to more severe and diﬀuse
cutaneous leishmaniosis, with multiple nodules over large
areas of skins.
ZVL is much more severe than ZCL, and it is caused
by the viscerotropic L. infantum. Viscerotropic parasites
addressed to the genus Leishmania have been classiﬁed into
fourspecies,precisely,L.donovani,L.archibaldi,L.infantum,
and L. chagasi. The last one is now considered a New World
synonymous of L. infantum [4]. In fact, L. infantum is
thoughttohavebeenimportedintotheAmericasbythedogs
ofEuropeansettlersduringthecolonization[18].Inhumans,
all these parasites cause visceral leishmaniosis, an acute, life-
threatening disease during which the agents multiply in the
macrophages of the reticuloendothelial system, resulting in
generalized symptoms like fever, splenomegaly, and pancy-
topenia. L. donovani and L. archibaldi cause anthroponotic
visceral leishmaniosis (AVL) that is only transmitted from
human to human via sandﬂy bites and aﬀects people of
all ages while ZVL from L. infantum aﬀects mainly young
children and is transmitted from dogs. The only domestic
andprimaryreservoirofthiszoonoticdiseaseisthedog[19],
inwhichL.infantumcausesthecanineleishmaniosis(CanL).
ZVL is a disease re-emerging in the whole Mediterranean
Basin [19]: about 200 cases are yearly reported in Italy,
usuallyinthesameareaswhereCanLisendemic[20].World-
wide reports show that sixty-six Old World and twenty-two
New World countries are endemic for human leishmaniosis.
The estimate yearly incidence of ZVL is 500,000 cases [21,
22]. About 90% of ZVL occur in rural and suburban areas of
ﬁve countries (Bangladesh, India, Nepal, Sudan, and Brazil);
however,thisnonuniformdistributionisduetotheevidence
that oﬃcial data are probably underestimated, because it was
obtained through incomplete, passive case detection [17].
The clinic evolution of ZVL can greatly vary according to the
immune status of the patient: in fact, it usually has a chronic
course, but in people with reduced immune response (e.g.,
HIV-aﬀected people) fulminant disease has been described
[23]. In the classic, chronic evolution, early symptoms in-
clude abdominal pain, weight loss, weakness, and typically
remittent febrile episodes, with two spikes per day. Later,
lymphnodes swelling and liver and/or spleen enlargement
mayoccur.Typically,thereishypergammaglobulinemiawith
circulating immune complexes and nephritis. Patients in the
ﬁnal stages of the disease show thrombocytopenia, bleeding,
haematuria, and consequent anemia. Death may occur
following hemorrhage and complications due to reduction
of the immune response.
3.CanineLeismaniasis(CanL):
Epidemiology, Pathogenesis, and
ClinicalSigns
Canine leishmaniosis (CanL) is a chronic visceral-cutaneous
syndrome, which clinical signs could noticeably change from
a patient to another: it may be manifested as a subclinical
infection,oftenself-limiting[24]orcanbeanonself-limiting
and severe illness [25]. The transmission of L. infantum from
domestic dogs to humans by the bite of previously infected
sandﬂies was ﬁrst demonstrated in 1930 [26, 27]. Since then,
many studies conﬁrmed the role of the domestic dog as
the main reservoir of ZVL [17]. In fact, dogs have a high
prevalence of both infection and infectiousness, have long-
lasting infections, and are common in the peridomestic envi-
ronment where usually the transmission to human occurs
[5]. During the past years the scientiﬁc interest in CanL has
grown considering the progressive increasing of the global
incidence of ZVL and its occurrence in areas previously not
involved, possibly as a consequence of global climate changes
[17, 28]. Moreover, it is possible that the zoonotic potential
of CanL has been enhanced, considering the more and
more abundant presence of immunocompromised humans,
particularly in developing countries [29–32]. However, even
if dogs are recognized as the most important peridomestic
reservoir of L. infantum infection to humans, only one study
has shown that the owner of an infected dog could be at
risk of transmission of the infection from his pet [33]. In
fact, the presence of an infected dog in a household does
not seem to increase the risk of infection for the members of
the family in endemic areas [25], as the infected sandﬂy can
transmit L. infantum in a range of 2.5km [34]. Pathogenesis
of CanL is common to others forms of leishmaniosis. In
fact, all protozoan of the genus Leishmania are parasites that
need two hosts to complete its life cycle: a phlebotomine
sandﬂy vector and a mammal. The arthropod harbors the
ﬂagellated extracellular promastigote while the nonﬂagel-
lated, intracellular amastigote develops in the mammal. The
metacyclic promastigote (e.g., the ﬁnal promastigote form)
is transmitted to a new mammal host, that can belong to
the same species of the previous extraphlebotomine host, or
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an infected female sandﬂy feed on the mammal, inoculating
promastigotes via the proboscis. Male sandﬂies are not eﬀec-
tive vectors as they are not hematophagous [35]. In dogs, the
subsequent course of infection is linked to the host immune
response and to the degree of persistence and multiplication
of the parasite [36]. As it has already been shown in
humans [37], the presence or absence of T-cell response is
important for the developing of clinical signs: analyses of
circulating lymphocites in symptomatic dogs have shown
l o wl e v e l so fC D 4 + and CD8+ T-cells and a decrease in
CD21+ B-cells and CD14+ monocytes, and changes related
to bone marrow parasite density [38]. The absence of an ad-
equate T-cell response leads to insuﬃcient control of the
parasite and consequent appearance of clinical signs, high
Leishmania-speciﬁc antibody levels, and high parasite bur-
dens in skin, bone marrow, spleen, liver, and lymphnodes
[14, 39]. Asymptomatic dogs, in which Leishmania infection
is manifested as a subclinical, self-limiting disease, are cha-
racterized by the presence of protective immunity that
is CD4+ T-cells-mediated [11, 40, 41]. On the contrary,
symptomatic dogs are characterized by disease susceptibility
associated to the production of a marked humoral non-
protective immune response and a reduced cell-mediated
immunity [36, 42]. Therefore, CanL can range from a mild
dermatitis associated with speciﬁc cellular immunity and
low humoral response to a severe disease characterized by
immunecomplexdepositionduetoamassivehumoral,non-
protective response and renal damage consequent to the
frequent development of glomerulonephritis and tubuloin-
terstitial nephritis [43, 44].
Clinical signs of CanL show after a period of incubation
from two to eight months [45] ,a n du pt oﬁ f t e e nm o n t h s
[46]. One author reported the development of clinical signs
in dogs living in a nonendemic country after 5–7 years they
had visited an endemic area [47]. Clinical signs vary widely
from a patient to another due to the diversity of immune
responses and the variety of organs aﬀected, resulting in
several clinical ﬁndings [36, 42, 48]. Any organ could be
potentially involved; however, some signs are more frequent
than others. The main groups of clinical signs of CanL are
described below.
3.1. Cutaneous Lesions. Cutaneous lesions are the most
common clinical manifestations of CanL, they are reported
in more than 50% of cases [36], even 90% according
to several authors [36, 47] ,a n da ne x t e n s i v er a n g eo f
dermatological entities have been described and classiﬁed in
groups (reported percentages are from a study of Ferrer on
43 dogs): (1) alopecia and peeling (nonpruritic exfoliative
dermatitis) generalized or localized over face, ears, and limbs
(60%); (2) ulcerative dermatitis with ulcers in the skin of
the limbs and joints (23%); (3) focal or multifocal nodular
dermatitis (11%); (4) pustular dermatitis and general exan-
thema (6%). Papular dermatitis has also been described [44]
and therefore considered as the ﬁfth group of main dermato-
logical entities associated to CanL [25]. Other less frequent
cutaneous manifestations are depigmentation, digital, and
nasal hyperkeratosis, while pyodermitis by Staphylococcus
spp. is a frequent complication [25, 49]. Onychogryphosis
has been reported as present in 75% of cases in a study by
Semiao-Santosetal.[50].Perionyxis andonychorrhexis have
also been reported [47, 50].
3.2. Lymphadenopathy and Splenomegaly. Lymphadenopa-
thy (increasing of size and consistency of lymph nodes) is
a very common clinical sign, usually appearing relatively
early during the course of the disease. The presence of this
clinical sign has been reported in the 93.5% of cases [36, 50].
The general increase of limph nodes size facilitate palpating
of superﬁcial ones, in particular, popliteal, prescapular, and
submaxillar [36]. Considerable splenomegaly have also been
described [25, 47].
3.3. Ocular Manifestations. Ocular manifestations are quite
frequent during CanL, being reported from 16 to 80% of
cases [25]. The most frequent eye lesions are conjunctivitis,
with mucous to mucopurulent conjunctivitis reported in
18.5% of cases [50]. These are characterized by a yellowish
secretion that adhere to the lacrimal margins while the
mucosa is usually pale, due to anemia [36]. Similarly, ble-
pharitis (exfoliative, ulcerative, or nodular), anterior uveitis
and keratoconjunctivitis have also been reported [51]. Kera-
toconjunctivitiscanalsoprogresstoulcerationandblindness
[52].Uncommonareocularconsequencesofsystemichyper-
tension(e.g.,retinaldetachment),reportedin5.7%ofhyper-
t e n s i v ed o g sw i t hC a n L[ 25, 53].
3.4. Renal Disease. Renal disease may be the only clinical
manifestation of CanL [25]. Glomerulonephritis and tubu-
lointerstitial nephritis due to the deposition of immune
complex are the most common pathological ﬁndings in
leishmaniotic dogs that develop chronic renal failure [43],
which is the principal cause of death in CanL [25, 36].
However, renal disease associated to this pathology does not
always reach these severe developments: membranoprolifer-
ative glomerulonephritis is usually associated with chronic
renal failure while dogs without clinical evidence of renal
disease more frequently reveal mesangioproliferative lesions
[54].
3.5. Other Clinical Signs. CanL is a systemic disease that
could involve many organs, so a variety of other clinical signs
are possible, often making diﬃcult diﬀerential diagnosis to
other diseases. Weight loss, locomotor abnormalities, apathy
and anorexia are still quite frequent, being reported in
15–30% of cases; less frequent are polydypsia, poliphagia,
polyuria, epistaxis, vomiting, and diarrhea [36, 50]. In par-
ticular, cachexia and muscular atrophy are common ﬁndings
in dogs at the ﬁnal stages of the disease, when locomotor
abnormalities are also frequent. These could be associated
to arthritis, osteomyelitis, and arthrosynovitis in uncommon
clinical forms of leishmaniosis [47, 55]. Other uncommon
clinical forms include neurological disease and polymyositis
[56], as well as various autoimmune and cardiovascular
disorders (pericarditis, vasculitis) [25].4 Veterinary Medicine International
4.CanineLeismaniasis(CanL):
LaboratoryDiagnosis
Accurate and early diagnosis of CanL is crucial to identify
infectious dogs and organize control strategies. In order to
diagnosis CanL, clinical, anatomopathological, and labora-
tory ﬁndings should be evaluated together. However, control
programs are usually based mostly on mass screening, there-
fore laboratory techniques will be primarily taken into con-
sideration: a large part of the CanL reservoir is composed by
infectedclinicallyhealthydogs.Asconcernsclinicalsignsand
anatomopathological ﬁndings in CanL patients, also useful
for the diagnosis in infected dogs with clinically evident
disease, we recommend to refer to the previous chapter.
Diﬀerent methods of laboratory diagnosis are currently
available, and they can be divided between (1) parasite
isolation(directandindirect)and(2)immunodiagnostictech-
niques for the detection of cellular and humoral responses
[36]. The detection of the parasite is the main conclusive
diagnosis and it is usually carried out directly through the
demonstration of amastigotes in smears or after culture of
samples (aspirates) obtained from cutaneous lesions, bone
marrow, lymphnodes, and spleen [25]. The most important
indirectmethodofdetectionoftheparasiteisthepolymerase
chain reaction (PCR), characterized by high sensitivity and
speciﬁcity. It can be carried out from samples of blood, skin,
lymphnodes, conjunctiva, and bone marrow [36]. Obtaining
blood could be the most simple and noninvasive procedure
in order to perform PCR, but the parasite load is often lower
than in other tissues. Therefore, the application of parasite
detection techniques is often diﬃcult when a high number
of animals have to be sampled for screening purposes. In
this cases, immunodiagnostic techniques are of great utility,
in order to detect anti-Leishmania circulating antibodies
(mainly IgG): immunoﬂuorescent antibody test (IFAT), en-
zyme linked immunosorbent assay (ELISA), and direct agg-
lutination test (DAT) are the most used methods. To date
the IFAT test, the most speciﬁc and sensitive among the
serological techniques mentioned above, is reasonably con-
sidered the “gold standard” for mass screening of dogs [57,
58]. In fact, infectiousness is positively associated with high
antiparasite antibody response and low CD4+ T-cell count
[11, 40, 41], therefore high antibody levels are considered
conclusive of a diagnosis of CanL [25, 38]. However, false-
positive results due to serological cross-reactivity with other
pathogens (e.g., Trypanosoma cruzi) have been described
[59] and low sensitivity in detecting asymptomatic dogs
has also been reported [60]. The cutoﬀ titre to distinguish
positive and negative results ranges from 1:40 to 1:160
according to diﬀerent laboratories [61].
5.Leishmania infantum Vectors: Sandﬂyand
Non-Sandﬂy Transmission Routes
Leishmaniainfantumistransmittedfromthecaninereservoir
tootherdogsorhumansviasandﬂiesbites.Thereisanexclu-
sive association between sandﬂy species and Leishmania
species due to speciﬁc enzyme and ligands present in the
gut of these insects: only speciﬁc Leishmania spp. are allowed
to attach to gut’s wall and replicate without being excreted
[62]. Therefore, the transmission of each Leishmania species
occurs only in that areas where the speciﬁc vectors species
are present. In particular, female sandﬂies of the genus
Phlebotomus (Europe, Asia, and Africa) and Lutzomya (Latin
America) are the vectors of L. infantum [19, 34, 35]. In the
countries of the Mediterranean Basin the most important
vector species is Phlebotomus perniciosus [63–65]. Other
proven sandﬂy vectors present in the Mediterranean Basin
and in the Middle East are P. ariasi, P. neglectus, P. perﬁliewi,
P. langeroni,a n dP. tobbi [5, 19, 35]. In northern Africa
also P. sergenti and P. arabicus have been reported as proven
vectors of L. infantum [25]. These arthropods are present
both in tropical and temperate areas, but in the last ones
they are usually active only during warm months, from
spring to autumn, at temperatures between 15◦ and 28◦C
[25, 35]. The importance of sandﬂy transmission routes in
the epidemiology of ZVL and CanL is demonstrated by the
spatial and temporal overlapping of clinical cases and the
presence of incriminated vector species [5]. For example,
new cases of autochthonous ZVL in humans have been
reported in areas of Northern Italy previously considered
free [20], in consequence to new CanL outbreaks [66–
68] and the proven northerly expansion of two speciﬁc
vector species P. perniciosus and P. neglectus [28]. This
situation has been attributed, just as new northward cases
of CanL, to climate changes [17]. A recent European Union-
funded project “Climate Change and Adaptation Strategies
for Human Health in Europe” (cCASHh) concluded that
so far there are no evidences that sandﬂy distributions in
Europe have altered after recent climate changes, but it
also stated that a considerable potential for climate-driven
changes could be in Leishmaniosis distribution in the future
[69, 70]. Moreover, the EDEN project (Emerging Diseases
in a Changing European Environment) has highlighted the
potential of leishmaniosis to expand to new territories with
its vector as environments change, and various researches
carried out in the framework of this project have come to
the conclusion that signiﬁcant changes have occurred in
the geographic distribution of CanL and VZL cases and of
ﬂebotominevectors,involvingareaspreviouslyconsideredas
nonendemic [71–74].
Non-sandﬂy transmission routes should be also consid-
ered. In fact, symptomatic CanL is characterized by wide-
spread dissemination not only in blood but also in other
body ﬂuids, like semen or saliva, therefore biting [5], blood
transfusions [75] ,a n du s e dn e e d l e s[ 76, 77] have been sug-
gested to be non-sandﬂy transmission routes, as well as
sexual contact [78], congenital transmission [79, 80]a n d
mechanicaldog-to-dogtransmissionviaticks[81].However,
non-sandﬂy transmission seems to play only a marginal role
in the epidemiology of leishmaniosis [25].
6.Leishmania infantum DogReservoir:
Methods of Control
T h ep r i m a r yo b j e c t i v eo ft h ec o n t r o lo fC a n Li st or e d u c e
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prevalenceindogs.Diﬀerentmethodsofcontrolareavailable
for the control of the L. infantum canine reservoir. Control
methods could be divided into two diﬀerent groups: (1)
methods aimed at infectious dogs (direct control methods)
and (2) methods aimed at vectors (indirect control meth-
ods).Asconcerntheﬁrstgroup,abigissueistoidentifywhat
dogsshouldbesubjectedtocontrolmethods.Infectiousdogs
shouldberecognized,andthisisnotaneasywork.According
to the guidelines by Solano-Gallego et al. [25], dogs in
CanL endemic regions could be divided into sick (animals
with clinical leishmaniosis) and healthy. Moreover, healthy
dogs encompasses both noninfected and infected clinically
healthy animals. Only part of infected clinically healthy
dogs could develop disease (potentially “presymptomatic”
dogs): in fact, there are CanL-infected dogs that could be
considered“resistant”toclinicalleishmaniosisthatwillnever
develop clinical signs. There is a debate about the degree
of infectiousness of infected clinically healthy and infected
sick dogs, also linked to the usefulness or not of therapeutic
treatment on dogs for the control of ZVL in humans.
Moreover, it is debated if only sick dogs are worth subjecting
to direct control methods (e.g., clinical treatment or culling)
in order to limit the transmission of L. infantum.I nf a c t ,
infectiousness would increase with clinical severity, but the
infectiousness of infected clinically healthy dogs would also
be suﬃciently high that direct control needs to be targeted
to all serologically positive dogs [5]. However, according to
a longitudinal study by Courtenay et al. [11], dogs infected
but “resistant” to clinical leishmaniosis would contribute
very little to transmission. So, direct control methods tar-
geted to infectious dogs (presymptomatic and symptomatic
dogs) could be eﬀective if a reliable test were available.
Although of undoubted utility in mass screening, IFAT is not
a sensitive and speciﬁc test to detect infectiousness, neither
are skin biopsies, in fact, studies comparing infectiousness
and parasite loads in the skin or lymphnodes have not shown
the presence of a correlation [82]. The use of quantitative
PCR for the assessment of skin parasite load could be
more informative [5], but to date the detection of anti-
Leishmania circulating antibodies with a serological titre
≥1:160 is the preferred screening method to identify dogs
with a very high chance to be infectious and, therefore,
worth to be subjected to direct control methods [19]. It is
obvious that all dogs (infectious and noninfectious) should
be subjected to indirect control methods. Hereinafter, direct
and indirect control methods are described, including their
eﬃcacy, advantages, and disadvantages.
6.1. Direct Control Methods
6.1.1. Culling. The removal of infectious, serologically pos-
itive dogs through euthanasia could seem the most obvious
direct control method of the Leishmania infantum reservoir.
In fact, this is a debated issue, as diﬀerent studies tried
to demonstrate the eﬃcacy of this tool, without reaching
deﬁnitive evidences [83, 84]. The new sensitivity of a large
part of population, particularly in most developed countries,
considers this kind of approach ethically unacceptable [7,
85]. For this reason, more and more countries are choosing
to follow only no-kill strategies for the control of free-
roaming dogs and, therefore, for the control of the canine
reservoir of ZVL. However, the main evidence against the
dog culling approach to control leishmaniosis is the failure
of large programs of systematic elimination of seropositive
dogs carried on during past years that did not result in
any reduction in the number of human cases [86]. A high
proportion of dogs should be euthanized to achieve eﬀective
reduction in disease transmission [87] ,a n dt h i si so f t e n
a too ambitious objective, mostly in undeveloped countries
with limited economic resources. Moreover, the diagnosis of
infectious dogs can be very diﬃcult: sometimes serological
diagnosis produces false negatives and often there is a long
interval before the eﬀective elimination of infectious dogs
[88]. Finally, the removal of dogs only subjected to serolog-
ical diagnosis can have counterproductive eﬀects: infected
dogs, when removed, would be replaced by susceptible dog
that could become infectious in a short time [11].
6.1.2. Treatment. Treatment of symptomatic or asymptom-
atic dogs with high levels of anti-Leishmania circulating
antibodies is the only way to reduce the infectiousness of
these subjects in countries where culling is not allowed.
Infectious dogs should always be treated, not only for ethical
reasons, but also for public health reasons. In fact, there is
a correlation between infectiousness of dogs and parasite
burden:thereductionofparasiteloadsaftertreatmentwould
reduce the possibility of transmission of Leishmania infan-
tum to vectors and, therefore, to other dogs or humans [89,
90]. Response to treatment vary from a patient to another
and according to the protocol used, but particularly for the
ﬁrst choice drugs it is normally quick: in few days weight
increases, cutaneous lesions reduce, blood parameters return
to normality, and there is general improvement of the dog’s
condition [36].
To date, there are diﬀerent protocols of treatment for
leishmaniosis in dogs, using drugs from diﬀerent categories.
The “classic” and still considered “ﬁrst choice” treatment
is based on the use of pentavalent antimonial compounds.
In particular, meglumine antimoniate (Glucantime), is the
most used commercial formulation, usually combined with
allopurinol, according to several diﬀerent protocols. Con-
sidering the possibility of signiﬁcant side eﬀects, many dif-
ferent protocols have been suggested, varying considerably
regarding the dosage, dose interval, and duration of treat-
ment. Possible adverse eﬀects may be arthralgias, myalgias,
gastrointestinalproblems,alterationsinhepaticfunctionand
nephrotoxicity [36]. The last one is the most severe eﬀect,
and occurs mostly in dogs with reduced glomerular ﬁltration
rate [25]. The preferred route for the administration of
antimonial compounds is subcutaneous [25]. Intramuscular
or intravenous administration has also been suggested [36],
eventhoughtheycouldbecauseof muscularﬁbrosis,abscess
formation [13], and thrombophlebitis [47]. Allopurinol is
always administered orally. Allopurinol has synergic eﬀect in
CanLtherapy,thereforeitisusedinmanydiﬀerentprotocols.
It is an inhibitor of xanthine oxidase, that results in the
inhibition of the synthesis of parasite proteins [91]. It has
scarce side eﬀects (xanthine urolithiasis) and therefore can6 Veterinary Medicine International
be used for long periods [92, 93]. The protocol based on the
combined use of antimonials and allopurinol considered as
“ﬁrst line treatment” by the guidelines from Solano-Gallego
et al. [25] and Oliva et al. [94] is: meglumine antimoniate
(MA) 75–100mg/kg/SID S.C. for 4–8 weeks + allopurinol
(A) 10mg/kg/BID P.O. for six months or more [95–98].
Another eﬀective protocol based on the use of the same
drugs is: MA 50–75mg/kg/BID S.C. for 1-2 months +
A 10–20mg/kg/die P.O. for 1–8 months [19, 99]. During
treatment clinicopathological parameters should be moni-
tored, including complete CBC, biochemical proﬁle, serum
protein electrophoresis, and urinalysis, after the ﬁrst month
of analysis and then at least every 3-4 months [25]. In
o r d e rt ol i m i ts i d ee ﬀects, modulation of doses according
to kidney and liver functions has also been used [9]: MA
75mg/kg/BID S.C. + A 20mg/kg/SID P.O. were used in
dogs with GOT, GPT, BUN and creatinine inside normal
range; MA 50mg/kg/SID S.C. and A 20mg/kg/SID P.O. were
used in dogs with liver or renal failure. In the same study,
the moment of stopping antimonial treatment was decided
on the basis of results from serum protein electrophoresis,
enduring the treatment until the albumin/globulin was
≥0.80.
The second choice “classic” treatment for the therapy of
CanLisamphotericinB:itisaverypowerfulanti-Leishmania
drug [100], but it is preferably administered by slow intra-
venous infusion [25, 101], although also subcutaneous
administration has been suggested [102]. The speed of intra-
venous infusion is closely related to the occurrence of side
eﬀects like trembling, fever, nausea, and vomiting [103].
Another important disadvantage of amphotericin B is its
severe nephrotoxicity, resulting in decreasing of the rate of
glomerular ﬁltration with consequent increasing in levels of
serum creatinine and urea nitrogen [36]. The recommended
protocol foresees the administration of doses from 0.1 to
1mg/kg/SID or twice per week (lower doses when admin-
istration is daily) I.V. for two months [101, 102]. The develo-
pment of formulations of amphotericin B in lipid carriers
has been performed to diminish toxicity [104], but these
products have high costs. Moreover, these are the ﬁrst line
drugs for the therapy of human leishmaniosis, so their
u s ei nd o g si sn o tr e c o m m e n d e dt oa v o i dd r u gp a r a s i t e
resistance [25]. Experimentally, liposomal amphotericin B
has been used in dogs at the dose of 3mg/kg/SID I.V. for
ﬁve consecutive days, intravenously: results were good, but
clinical signs usually reappeared after 4–6 months [105].
Recently, miltefosine has been successfully used in asso-
ciation with allopurinol for the treatment of CanL [6, 106].
It is an antineoplastic agent that has proved to be eﬃcient
against Leishmania [107], now registered for the use in dogs
as Milteforan. The main advantages of this drug are the oral
administration and the low toxicity, even if some gastroin-
testinal side eﬀects (vomiting, diarrhea) have been reported,
mostly at high doses, so that administration with food is
recommended [108, 109]. Another possible side eﬀect could
be the early development of drug resistance due to the long
half-life of this agent [110]. The protocol successfully used
[6] foresees the administration of miltefosine 2mg/kg/SID
P.O. for four weeks and allopurinol 10mg/kg/BID P.O. for
six months.
6.1.3. Vaccine and Immunotherapy. The use of an anti-
Leishmania dog vaccine could be the most practical and
eﬃcient tool for the control and, possibly, the eradication of
the disease in endemic areas [3, 87]. In the last years, many
studies have been carried on several immunoprophylactic
vaccine candidates, in order to ﬁnd an eﬃcient tool able to
directly prevent leishmanian infections [111–117]. To date,
onlytwovaccineshavebeenlicensed,bothinBrazil,precisely
the Leishmune (Fort Dodge Animal Health) and the Leish-
Tec (Hertape Calier Sa` ude Animal). The second one consists
of adenovirus expressing a Leishmania donovani A2 antigen,
but only partial results on ﬁeld trials testing its eﬃcacy have
been published so far [14, 118, 119]. Leishmune vaccine has
already shown its eﬃcacy in various ﬁeld studies [15, 113,
120, 121]. It is a FML-saponin vaccine that protect 98%
of vaccinated dogs [15], blocking the transmission of the
disease to sandﬂy vectors. This tool acts on a crucial moment
of the life cycle of Leishmania infantum, with important
epidemiological eﬀects: in fact, it was demonstrated that
vaccinated dogs do not present the parasite in blood,
skin and lymph nodes [120], not exposing the parasite
to sandﬂies. In some areas of Brazil, the anti-Leishmania
vaccination of healthy dogs has been used as a preventive
tool systematically used in association to regular culling of
serologically positive dogs, with encouraging eﬀects: from
2004 to 2006 the vaccination of 5.7% of the healthy dogs
led to a decrease of 25% of cases of CanL in dogs and
of 61% of cases of ZVL in humans [12]. Anti-Leishmania
vaccination is debated because of the possible eﬀects on
the serological response of vaccinated, healthy dogs: after
vaccination they could present seroconversion, therefore
being indistinguishable from infectious dogs [15, 16]. So,
serological control campaigns, employing either ELISA or
IFAT serological screening tests, would be no more useful,
because more than 70% of vaccinated dogs would result
positive [12, 16]. Recently, it has been reported that the
use of a speciﬁc anti-Leishmania ELISA test, suggested by
the Brazilian Ministry of Health, would be able to detect
only 1.3% of positivity among uninfected vaccinees [12],
therefore not interfering with regular serological control
campaigns.
The anti-Leishmania vaccine has also demonstrated its
eﬃcacy as immunotherapic agent, used alone or in asso-
ciation with allopurinol and amphotericin B (chemoim-
munotherapy) for the treatment of symptomatic dogs [1].
For these purposes, a vaccine formulation, diﬀerent from
the one registered for prophylactic purposes, was used, with
positive eﬀects both considering immunotherapy (reduction
of symptomatic cases from 100% to 38%) and chemoim-
munotherapy (reduction of symptomatic cases from 100%
to 12%). In particular, the combination chemotherapy-
vaccine (chemoimmunotherapy) resulted very eﬀective in
eliminating also latent infections, given that 80% of patients
showed PCR negative lymphnodes after eight months of
treatment, versus only 33% of patients with immunotherapy
alone.Veterinary Medicine International 7
6.2. Indirect Control Methods
6.2.1. Repellent Tools. During the last decade, a number of
studies have been carried out demonstrating the eﬃcacy of
topical insecticides treatment of dogs exposed to sandﬂy
bites in order to control the canine reservoir of Leishmania
infantum [5, 6, 25]. It is now widely accepted that the
prevention of sandﬂy bites on dogs is eﬃcient in reducing
not only the incidence of CanL [7, 122], but also the risk
of human infections [33, 123]. There are three diﬀerent
types of topical preventive tools, namely, collars, spot-on
and spray formulations, all based on synthetic pyrethroids at
various concentrations: permethrin 50%-imidacloprid 10%
(spot-on), permethrin 65% (spot-on), permethrin 1.9%-
pyriproxyfen 0.02% (spray), and deltamethrin 4% (collar).
These tools are eﬃcient through two actions. (1) antifeeding
eﬀect: the presence of the insecticide on the skin has
a strong repellent eﬀect, so the sandﬂy has only a ﬂeeting
contact with the dog, that is suﬃcient to disorientate and
irritate the insect, resulting in absence or reduction of the
blood feeding; (2) insecticide eﬀect: usually the sandﬂy,
even if disorientated and incapable of feeding, remains on
the skin for quite long time, absorbing a dose suﬃcient
to achieve toxic eﬀects [35, 124]. Therefore, these topical
insecticides not only manage to prevent sandﬂy bites and,
consequently, L. infantum transmission, but also can reduce
the number of infectious phlebotomus by direct elimination
of them. Deltamethrin-impregnated collars have antifeeding
and lethality eﬀects for six months [6], while spot-on and
spray formulations have shorter eﬀects, so they have to
be applied at least once a month [7]. On the contrary,
because of the slow release of the insecticide, collars achieve
full protective activity only 1 week after application while
spot-on formulations need 24–48 hours, and sprays are
immediately active [123] .C o l l a r sh a v ed e m o n s t r a t e dt oh a v e
ap r o t e c t i v ee ﬀect from 72% to more than 90% according to
diﬀerent studies [6, 36, 122]; moreover, they have shown to
have a mortality eﬀect ranging from 30% to 67% [36]. Spot-
on formulations have demonstrated to be more eﬀective,
withaprotectionraterangingfrom88.9%to97.7%andeven
to 100%, according to the intervals between one application
and another (once or twice a month) [7, 124, 125]. On the
contrary,theinsecticideeﬀectofspot-onformulationsseems
to not diﬀer very much from the one attributed to collars,
ranging from 23% to 67% [123]. The only available spray
formulation has shown a repellent eﬃcacy of 71.4% but
an insecticide eﬀect just of 7.2%, after 21 days [126, 127].
Field studies have been performed for collars and spot-on
formulations, in order to evaluate the impact of mass use
on the incidence of leishmaniosis, reporting reductions from
50% to 53% in tropical or subtropical countries [128, 129]
and from 86% (collars) to over 90% (spot-on) in temperate
countries [7, 9, 122, 130]. Moreover, in an Iranian study
basedontheapplicationofdeltamethrinimpregnatedcollars
a reduction of 43% of the odds of seroconversion in children
was reported [33], highlighting the indirect eﬀects of these
tools on human visceral leishmaniosis. These are important
achievements, but even more important results could be
obtained in the future through these tools. In fact, so far
these control methods have been used only in reduced and
controlled areas: the application of topical insecticides in
wider areas, involving entire communities and a consistent
percentage of the dog population (free-roaming and not)
could have a greater eﬀect on the incidence of both CanL and
ZVL.
6.2.2. Environmental Control. The eﬃcacy of environmental
insecticides in order to control the sandﬂy population is
debated, considering high costs, diﬃculties in application,
pollution concerns, and the possibility of resistances. There
is a great variety of species of vectors, and in some cases
the presence of resistance was reported, in particular for
Phlebotomus papatasi (resistance to DDT, permethrin, and
lambdachyalothrin)andPhlebotomusargentipes(permethrin
and deltamethrin) [131]. However, other studies have
reported that sandﬂy control by insecticides should be
av e r ye ﬀective control method: the increase of sandﬂy
mortality reduces the number of vectors, directly inﬂuencing
the disease transmission [87]. Synthetic pyrethroids are at
present the most used anti-sandﬂy insecticides, even if their
short-lived residual activity compared to DDT could be
a limitation and a reason of the low eﬃcacy sometimes
reported [132]. The eﬀectiveness of control campaigns based
on insecticide spraying for the reduction of ZVL cases was
reported in Italy [133], India, Greece, Israel [36] and in
China [84]. In particular, the eﬃcacy of insecticide spraying
was reported to be more evident in the intra- or peridomi-
ciliary environment, rather than reduce the overall sandﬂy
population [134], as this kind of control is eﬀective on adult
insects only, because it is not known were immature forms
live [133]. Moreover, spraying in areas like forests, burrows,
caves, and other places where sandﬂy larvae and pupae
are suspected to live is technically very diﬃcult [36], and
could have eﬀects on other insects species, with consequent
environmentaldamages.Ithasbeensuggestedtoconcentrate
spraying in the peridomiciliary environment to the inside
walls of houses, doors, windows, kennels, hen houses, and
drains [36] in order to maximize its eﬀect against indoor-
bitingvectors.Recently,theuseofinsecticide-treatednetshas
been suggested as a preventive tool for ZVL in humans [135,
136]. The reduction of microhabitats favorable to sandﬂies
hasalsobeenreportedasasteptobetakeninordertoachieve
eﬀective prevention [25]. However, the use of repellent tools
on dogs remains the most eﬀective antivectorial method to
control the L. infantum canine reservoir, and the use of
environmental control in association to spot-on formulation
should be particularly eﬃcient in areas with large and
concentrate dog populations (i.e., dog shelters).
6.3. Contemporary Use of Direct and Indirect Methods. A
number of studies have shown the eﬃcacy of single control
methods of the Leishmania infantum dog reservoir, inducing
the ministry, health organizations, and groups of scientists to
suggest the contemporary use of diﬀerent tools, particularly
preventive and therapeutic tools, in order to enhance their
eﬀects [19, 35, 36, 133]. However, these guidelines reported
the absence of ﬁeld studies or mathematically predictive
studies on the eﬀect of this “holistic” approach on the8 Veterinary Medicine International
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Figure 1: Evolution of prevalence and incidence of serological reac-
tivity versus Leishmania infantum in two dog shelters during a 4-
year period of contemporary use of direct (treatment with meglu-
mine antimoniate and allopurinol) and indirect (spot-on repellent
formulation imidacloprid 10%-permethrin 50%) control methods
[9].
prevalence and the incidence of leishmaniosis [19]. It has
been hypothesized that reinfection in endemic areas is likely
[25], due to the persisting action of sandﬂies also on subjects
treated with therapeutic protocols [137]. Recently, a ﬁeld
study of the authors [9] reported long term eﬀects (4-
year period) of therapeutic treatment associated with the
application of spot-on preventive tools. The retrospective
study was carried on in a dog shelter sited in an endemic
area in Central Italy, reporting a signiﬁcant, progressive
reduction of prevalence and incidence of serologic reactivity
to L. infantum with a very low rate of relapses (only 8%
after 4 years in a pool of 67 subjects that were already
seropositive at the beginning of the study). A total of 656
dogs sheltered in a municipal dog kennel were included
in the study. Antimonial treatment was administered to
animals assigned to one of the following three classes:
(1) serological titre ≥ 1:160, (2) serological titre = 1:80,
albumins/globulins ratio < 0,80, and (3) serological titre =
1:80 titre, albumins/globulins ratio ≥ 0,80, and presence
of clinical signs of CanL. The therapeutic protocol was
based on the administration of meglumine antimoniate
and allopurinol. Doses were individually adjusted according
to kidney and liver functions (meglumine antimoniate
75mg/kg/BID + allopurinol 20mg/kg/SID in dogs with
normal functions, meglumine antimoniate 50mg/kg/SID
+ allopurinol 20mg/kg/SID in dog with kidney or liver
failure). Antimonial treatment endured until the serum
protein electrophoresis gave an albumins/globulins ratio ≥
0.80; however, it was never longer than 12 months or shorter
than 2 months. Allopurinol administration continued until
completeserumproteinelectrophoresisnormalization.Since
the second year of the study a spot-on preventive treatment
was applied once a month to all dogs that were in the shelter,
using imidacloprid 10%-permethrin 50% (Advantix; Bayer;
Germany) at a dose of 1mL/10kg. A progressive reduction
of prevalence and incidence of seroreactivity to L. infantum
was observed. In particular, during the four-year period
seroprevalence was lowered from 10.8% to 4% (χ2 = 22.02;
P = 0.000, signiﬁcant); while incidence was reduced from
8.92% to 1.63% (χ2 = 52.226; P = 0.000, signiﬁcant
Figure 1). It should be highlighted that the introduction of
the association of preventive and curative treatment was
followed by a signiﬁcant reduction in prevalence from the
second to the third year of study (reduction of prevalence
from 10.63 to 6.41; χ2 = 6.90; P = 0.009), which contrasts
with what had been observed from the ﬁrst to the second
year, probably as a consequence of the absence of preventive
treatment (reduction of prevalence from 10.79 to 10.63;
χ2 = 0.08; P = 0.928, not signiﬁcant). The very low rate
of relapses could be considered as the key of this success.
In fact, previous studies using antimonial treatment without
preventing tools had reported seroreversion rates of 32%
[138], 74.3% [99], 39.6% [139], and 86% [140]; these are
values much more higher than the 8% reported in the
research above described [9]. However, more studies are
needed in order to conﬁrm the role of preventive tools in
reducing the rate of relapses and reinfections in endemic
areas.
7. Conclusions
The domestic dog is the most important natural reservoir
of Leishmania infantum and, therefore, it is crucial in the
transmission of both canine leishmaniosis and zoonotic
visceral leishmaniosis. A number of control methods of
the L. infantum canine reservoir have been experimented,
but at present the use of preventive tools directly applied
on dogs seems to be the most successful one. Culling of
infectious animals is now widely considered unacceptable
from an ethical point of view: more and more countries are
producing new “no-kill” laws with which control programs
must necessarily deal. Moreover, it has been reported that
this kind of approach often fails in achieving good results
concerning its eﬀects on reducing both the number of
human and canine cases, particularly if applied without
the contemporary use of repellent tools [86]. Treatment of
symptomatic dogs could seem too costly to aﬀord for many
countries but, according to animal welfare laws and the new
“humane” sensitivity of a large part of the population, the
absence of therapies could be intended as maltreatment and
therefore unacceptable [141]. The absence of treatments can
also be a risk for public health, considering the correlation
between infectiousness of dogs and parasite burden [89, 90].
The contemporary use of more than one control method has
beenrepeatedlysuggestedinthepastinordertoenforcetheir
eﬃcacy [19, 25] and, in particular, the use of repellent tools
can integrate the use of therapeutic treatments improving
their eﬀects and, therefore, their usefulness and aﬀordability.
Moreover, the community-wide use of repellent tools (spot-
on or impregnated collars) could be a valid alternative or
support to control programs based on dog euthanasia, both
considered for their proven eﬃcacy and limited costs. TheVeterinary Medicine International 9
anti-Leishmania vaccination has been successfully used [12]
anditcouldbeavaluabletoolinordertoimplementeﬃcient
surveillance programs to control the L. infantum canine
reservoir [3]. However, until a certain and commonly recog-
nized diagnostic method will not be available to distinguish
vaccinated from seropositive individuals, the use of this tool
on large-scale-control programs should not be suggested yet.
At present, repellent tools associated with the treatment of
infectious dogs seems to be the most desirable and widely
accepted approach in order to control the L. infantum canine
reservoir.
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